For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Tirzepatide

Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)

Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Where to buy · live market data

Who's worth your money for Tirzepatide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 25 scored sellers

$1.50/mg

$1800 · 1200mg · 99.1% purity

Best value

Lowest $/mg among scored sellers

$0.50/mg

$10.00 · 20mg · 99.8% purity

Most tested

57 independent COAs on file

$3.95/mg

$158 · 40mg · 99.9% purity

Average price

$3.95/mg

Sellers

47

45-day trend

-5%

40 of 47 sellers have a current price· 4 stale hidden· 11 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tirzepatide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tirzepatide

CAS

2023788-19-2

Molecular formula

C225H348N48O68

Sequence

YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide

Typical dose range

2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)

Half-life

~5 days (~120 hours)

Independent evidence

COAs for Tirzepatide

478 third-party tests across 56 vendors. Each card links to the full report.

All 478 COAs for Tirzepatide →
Measured purity 82.3%–100.0% across 311 COAs
Measured purity over time
✓ Vendor-published
99.57 %
Oct 2026
Kovera Labs

For

Tirzeppatide

by Reta One Labs· batch TZ201026

COA on file
Aggregated · 3rd-party listing
99.68 %
Sep 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ60-05

Aggregated · 3rd-party listing
99.85 %
Aug 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2608-B

Aggregated · 3rd-party listing
99.68 %
Aug 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2608-A

✓ Vendor-published
99.90 %
Aug 2026
ILS Laboratories

For

Tirzepatide

by Sunrise Bioresearch· batch GLP230JUL26-01

COA on file
Aggregated · 3rd-party listing
99.92 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5001072226TZ

Aggregated · 3rd-party listing
99.92 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5001572326TZ

Aggregated · 3rd-party listing
99.77 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5000572226TZ

Aggregated · 3rd-party listing
99.68 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by NovaForge Labs· batch LOT-TR-QSCT1

Aggregated · 3rd-party listing
99.99 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR10-1

Aggregated · 3rd-party listing
99.97 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR30-1

Aggregated · 3rd-party listing
99.87 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR60-1

Aggregated · 3rd-party listing
99.99 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5003071726TZ

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-F

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Finnrick Analytics

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-D

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-C

Aggregated · 3rd-party listing
99.88 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Crush Research· batch CR-2XAG-60-2607-Purple

Aggregated · 3rd-party listing
100.00 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Artisan Aminos· batch AA-TRZ220-049

✓ Vendor-published
99.59 %
Jul 2026
Kovera Labs

For

Tirzeptide

by Ignite Peptides· batch IP-2607-127

COA on file
✓ Vendor-published
99.51 %
Jul 2026
Kovera Labs

For

Tirzepatide

by Ignite Peptides· batch IP-2607-797

COA on file
Aggregated · 3rd-party listing
99.68 %
Jul 2026
Vanguard Laboratory Strong

For

Tirzepatide

by Certified Peptides· batch TIR070226

Aggregated · 3rd-party listing
99.90 %
Jul 2026
BTLabs Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2606-A

Aggregated · 3rd-party listing
100.00 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ40-15

Research depth

23 citations indexed for Tirzepatide

All research on Tirzepatide →

cohort · 2026

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.

Study · 2026

Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort

Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.

cohort · 2026

Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty

Purpose Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, whereas semaglutide is selective for the GLP-1 receptor.

animal · 2026

Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling

Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.

Study · 2026

Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.

Study · 2026

Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series